UY32711A - Nueva forma cristalina de pemirolast - Google Patents

Nueva forma cristalina de pemirolast

Info

Publication number
UY32711A
UY32711A UY0001032711A UY32711A UY32711A UY 32711 A UY32711 A UY 32711A UY 0001032711 A UY0001032711 A UY 0001032711A UY 32711 A UY32711 A UY 32711A UY 32711 A UY32711 A UY 32711A
Authority
UY
Uruguay
Prior art keywords
pemirolast
crystal form
new crystal
new
sodium salt
Prior art date
Application number
UY0001032711A
Other languages
English (en)
Spanish (es)
Inventor
Perlberg Anett
Viertelhaus Martin
Ulrika Rosenstroem
Horvath Karol
Original Assignee
Cardoz Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardoz Ab filed Critical Cardoz Ab
Publication of UY32711A publication Critical patent/UY32711A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Secondary Cells (AREA)
  • Dental Preparations (AREA)
UY0001032711A 2009-06-16 2010-06-15 Nueva forma cristalina de pemirolast UY32711A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18734809P 2009-06-16 2009-06-16
US18735509P 2009-06-16 2009-06-16

Publications (1)

Publication Number Publication Date
UY32711A true UY32711A (es) 2011-01-31

Family

ID=43264726

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032711A UY32711A (es) 2009-06-16 2010-06-15 Nueva forma cristalina de pemirolast

Country Status (31)

Country Link
US (3) US20120157415A1 (enExample)
EP (2) EP3141549A1 (enExample)
JP (2) JP5722317B2 (enExample)
KR (2) KR20170049645A (enExample)
CN (1) CN102596202B (enExample)
AR (1) AR077915A1 (enExample)
AU (1) AU2010261540B2 (enExample)
BR (1) BRPI1015559A2 (enExample)
CA (1) CA2765408A1 (enExample)
CY (1) CY1118413T1 (enExample)
DK (1) DK2443120T3 (enExample)
EA (1) EA025865B1 (enExample)
ES (1) ES2613059T3 (enExample)
HR (1) HRP20170023T1 (enExample)
HU (1) HUE032978T2 (enExample)
IL (1) IL216670A (enExample)
LT (1) LT2443120T (enExample)
ME (1) ME02685B (enExample)
MX (1) MX2011013676A (enExample)
NZ (1) NZ596747A (enExample)
PL (1) PL2443120T3 (enExample)
PT (1) PT2443120T (enExample)
RS (1) RS55558B1 (enExample)
SA (1) SA114350792B1 (enExample)
SG (1) SG176295A1 (enExample)
SI (1) SI2443120T1 (enExample)
SM (2) SMT201700085T1 (enExample)
TW (1) TWI504599B (enExample)
UY (1) UY32711A (enExample)
WO (2) WO2010146348A2 (enExample)
ZA (1) ZA201109045B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510837A (ja) * 2009-11-13 2013-03-28 カルドズ・アーベー 全身性軽度炎症の新しい処置
AU2013381855B2 (en) * 2013-03-09 2018-08-02 Chiesi Farmaceutici S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20160243122A1 (en) 2014-10-23 2016-08-25 Rspr Pharma Ab Use of pemirolast in the treatment of acute asthma
WO2016102941A1 (en) 2014-12-22 2016-06-30 Rspr Pharma Ab New combination of pemirolast and montelukast
GB201518831D0 (en) 2015-10-23 2015-12-09 Rspr Pharma Ab New use
JP6596697B2 (ja) * 2016-10-03 2019-10-30 ブリベンションファーマシューティカル(シャンハイ)インコーポレイテッド Trhアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
JP2504788B2 (ja) 1987-11-10 1996-06-05 東京田辺製薬株式会社 9−メチル−3−(1H−テトラゾ―ル−5−イル)−4H−ピリド[1,2−a]ピリミジン−4−オンカリウム塩の水性製剤
JP2837449B2 (ja) * 1989-08-11 1998-12-16 東京田辺製薬株式会社 ピリド[1,2―a]ピリミジン誘導体の製造法
ITMI20011764A1 (it) 2001-08-10 2003-02-10 Dinamite Dipharma Spa Metodo per l'ottenimento del pemirolast ad elevata purezza
US8686189B2 (en) 2005-09-16 2014-04-01 Daiichi Sankyo Company, Limited Optically active diamine derivative and process for producing the same
ES2394984T3 (es) 2006-12-18 2013-02-07 Cardoz Ab Nueva combinación para uso en el tratamiento de trastornos inflamatorios
AU2007336077A1 (en) 2006-12-20 2008-06-26 Cardoz Ab New combination for use in the treatment of inflammatory disorders

Also Published As

Publication number Publication date
JP2012530118A (ja) 2012-11-29
BRPI1015559A2 (pt) 2016-04-26
EA201200017A1 (ru) 2013-10-30
US20120157415A1 (en) 2012-06-21
MX2011013676A (es) 2012-02-08
US20140329839A1 (en) 2014-11-06
AU2010261540B2 (en) 2016-04-14
CY1118413T1 (el) 2017-06-28
CA2765408A1 (en) 2010-12-23
TWI504599B (zh) 2015-10-21
SMT201700085B (it) 2017-03-08
WO2010146348A2 (en) 2010-12-23
IL216670A0 (en) 2012-02-29
JP5722317B2 (ja) 2015-05-20
PL2443120T3 (pl) 2017-04-28
WO2010146341A3 (en) 2011-03-03
ME02685B (me) 2017-06-20
WO2010146348A9 (en) 2012-05-03
CN102596202A (zh) 2012-07-18
WO2010146348A3 (en) 2011-03-03
WO2010146341A2 (en) 2010-12-23
HRP20170023T1 (hr) 2017-03-10
SMT201700085T1 (it) 2017-03-08
ZA201109045B (en) 2013-05-29
EP3141549A1 (en) 2017-03-15
KR20120032530A (ko) 2012-04-05
IL216670A (en) 2017-02-28
AU2010261540A2 (en) 2012-01-19
LT2443120T (lt) 2017-02-10
ES2613059T3 (es) 2017-05-22
DK2443120T3 (en) 2017-01-09
AR077915A1 (es) 2011-10-05
US20170202839A1 (en) 2017-07-20
HUE032978T2 (hu) 2017-11-28
EA025865B1 (ru) 2017-02-28
SG176295A1 (en) 2012-01-30
PT2443120T (pt) 2017-02-08
SI2443120T1 (sl) 2017-04-26
SA114350792B1 (ar) 2015-11-10
CN102596202B (zh) 2015-01-21
NZ596747A (en) 2014-01-31
TW201100422A (en) 2011-01-01
KR20170049645A (ko) 2017-05-10
US9006431B2 (en) 2015-04-14
EP2443120B1 (en) 2016-11-02
EP2443120A2 (en) 2012-04-25
AU2010261540A1 (en) 2012-01-19
JP2015120750A (ja) 2015-07-02
RS55558B1 (sr) 2017-05-31

Similar Documents

Publication Publication Date Title
CO6852084A2 (es) Nuevos compuestos sustituidos con halógeno
ECSP11011444A (es) Inhibidores del canal de potasio medular externo renal
CR20130369A (es) Novedosos derivados heterocíclicos
PL3512252T3 (pl) Schematy przekazywania komunikatów o awarii
CR20120297A (es) Espironucleósidos uracílicos oxetánicos
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
EA201590321A1 (ru) Дейтерированный барицитиниб
BRPI1010795A2 (pt) compostos antivirais
UY34074A (es) Composición oftálmica de olopatadina altamente concentrada
CR20110432A (es) Pirimidinas fusionadas
PT2623498E (pt) Sal de sódio de 6-fluoro-3-hidroxi-2-pirazino-carboxamida
DOP2010000053A (es) Derivados de pirrolidin -2-ona como moduladores del receptor de androgeno
CR20130539A (es) Triazolopiridinas
CR20130419A (es) Derivados heterocíclicos de amina
FIC20260012I1 (fi) Molidustaatti, erityisesti molidustaattinatrium
CR20150084A (es) 2-oxo-2,3-dihidro-indoles
EP2423203A4 (en) CRYSTAL OF A BENZOXAZINONE COMPOUND
CY1118413T1 (el) Κρυσταλλικη μορφη πεμιρολαστης
CL2009001973S1 (es) Mostrador.
CR20110275A (es) 3-aminociclopentancarboxamidas como moduladores del receptor quimiocina
CR20120169A (es) Procesos para la preparación de 2-(1-feniletil)-isoindolin-1-ona
MX2014002454A (es) Nueva forma de cristal.
CL2010000016S1 (es) Seccion de una llave ciega.
UA113753C2 (xx) Фенілзаміщені кетоеноли для боротьби з паразитами риб

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190207